Biotech News
Related news
CORTCorcept2026-06-06 20:45 EST
Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®
CORTCorcept2026-06-17 20:28 EST
Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome
VKTXViking Therapeutics2026-10-21 20:05 EST
Viking Therapeutics to Report Financial Results for Third Quarter 2026 on October 28, 2026
VKTXViking Therapeutics2026-10-14 11:05 EST
Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity
NBIXNeurocrine Biosciences2026-05-01 20:05 EST
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Durable Hormone Control, Reduced Glucocorticoid Exposure and Meaningful Clinical Improvements in Pediatric Patients with Classic Congenital Adrenal Hyperplasia
NBIXNeurocrine Biosciences2026-04-22 20:05 EST
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia
AMPHAmphastar Pharmaceuticals, Inc.2020-10-06 10:00 EST
Amphastar Pharmaceuticals Receives FDA Approval for Atropine Sulfate Injection
Corcept
Cortisol Modulation Platform Corcept Therapeutics develops medicines that selectively modulate the glucocorticoid receptor and the effects of cortisol. Its portfolio spans endocrinology, oncology, metabolism and neurology. Cushing’s Syndrome Franchise Corcept has an established commercial business treating hypercortisolism in patients...
Recent company news
CORTCorcept2026-11-03 21:05 EST
Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update
CORTCorcept2026-10-27 20:05 EST
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
CORTCorcept2026-10-26 12:00 EST
Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer
CORTCorcept2026-10-20 20:00 EST
2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes
CORTCorcept2026-09-23 12:00 EST
Corcept Announces Planned Leadership Transition
Stock data
- Close
- 71.63 USD
- Market cap
- 7.64B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States